RxDoctor Payments Data

Jason McKenzie, DO

Family Medicine · Sparks, NVNPI 1922085265

Payments from drug & device makers

$456in general payments, 2019–2025

Across 27 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$119
  • Amarin Pharma, Inc.$74
  • Merck$46
  • Novo Nordisk$39
  • Kowa Pharmaceuticals America, Inc.$34
  • Pfizer$30
  • plus $114 from 6 others

What the payments were for

  • Food & beverage$456100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$456 in reported general payments places this provider in the 55th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$134,479
Medicare patients
235
Services billed
1,796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$64,439
JardianceEmpagliflozin45$60,908
EliquisApixaban41$49,727
RybelsusSemaglutide20$33,948
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog26$31,838
TrulicityDulaglutide13$17,585
XareltoRivaroxaban19$16,053
Amlodipine-ValsartanAmlodipine Besylate/Valsartan225$13,135
FarxigaDapagliflozin Propanediol15$11,569
Incruse ElliptaUmeclidinium Bromide16$8,359
Valsartan196$8,194
Advair HfaFluticasone Propion/Salmeterol25$7,795
Combivent RespimatIpratropium/Albuterol Sulfate13$6,174
Atorvastatin Calcium482$5,964
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide132$4,985

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$39$98,38659 claims
PfizerEliquis$30$49,72741 claims
Lilly USA, LLCTrulicity$15$17,58513 claims
GSKIncruse Ellipta$119$8,35916 claims
AbbVieSynthroid$19$1,35025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 902 family medicine providers in Nevada.

Other family medicine in Sparks

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →